{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:14:46Z","timestamp":1777630486471,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.bone.2015.03.002","type":"journal-article","created":{"date-parts":[[2015,3,8]],"date-time":"2015-03-08T04:31:14Z","timestamp":1425789074000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial"],"prefix":"10.1016","volume":"75","author":[{"given":"Chi Chiu","family":"Mok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling Yin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok Man","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2015.03.002_bb0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1507\/endocrj.53.27","article-title":"The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis","volume":"53","author":"Kaji","year":"2006","journal-title":"Endocr J."},{"key":"10.1016\/j.bone.2015.03.002_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bone.2006.02.005","article-title":"High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study","volume":"39","author":"Angeli","year":"2006","journal-title":"Bone."},{"key":"10.1016\/j.bone.2015.03.002_bb0015","first-page":"678","article-title":"De Waure C, et al; for Lazio-GISMO group","volume":"29","author":"Villa","year":"2013","journal-title":"Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population. Gynecol Endocrinol."},{"key":"10.1016\/j.bone.2015.03.002_bb0020","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.bone.2015.03.002_bb0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","article-title":"Fracture risk with intermittent high-dose oral glucocorticoid therapy","volume":"56","author":"De Vries","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2015.03.002_bb0030","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.bone.2015.03.002_bb0035","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/jbmr.362","article-title":"Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"26","author":"Hansen","year":"2011","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bone.2015.03.002_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrrheum.2009.259","article-title":"Management of glucocorticoid-induced osteoporosis","volume":"6","author":"Compston","year":"2010","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.bone.2015.03.002_bb0045","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.beem.2014.07.002","article-title":"Secondary osteoporosis: Pathophysiology & diagnosis","volume":"28","author":"Emkey","year":"2014","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"10.1016\/j.bone.2015.03.002_bb0050","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jcb.21651","article-title":"Wnt signaling acts and is regulated in a human osteoblast differentiation dependent manner","volume":"104","author":"Eijken","year":"2008","journal-title":"J Cell Biochem."},{"key":"10.1016\/j.bone.2015.03.002_bb0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0167-4889(03)00100-9","article-title":"Dexamethasone induces caspase activation in murine osteoblastic MC3T3\u2013E1 cells","volume":"1642","author":"Chua","year":"2003","journal-title":"Biochim Biophys Acta."},{"key":"10.1016\/j.bone.2015.03.002_bb0060","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1359\/JBMR.041233","article-title":"Influence of glucocorticoids on human osteoclast generation and activity","volume":"20","author":"Sivagurunathan","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bone.2015.03.002_bb0065","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2015.03.002_bb0070","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.bone.2015.03.002_bb0075","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.bone.2015.03.002_bb0080","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4065\/80.7.856","article-title":"Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women","volume":"80","author":"Recker","year":"2005","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.bone.2015.03.002_bb0085","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","article-title":"Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis","volume":"28","author":"Penning-van Beest","year":"2006","journal-title":"Clin Ther."},{"key":"10.1016\/j.bone.2015.03.002_bb0090","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1185\/030079908X297358","article-title":"Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis","volume":"24","author":"Penning-van Beest","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.bone.2015.03.002_bb0095","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00198-014-2619-3","article-title":"Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis","volume":"25","author":"Cairoli","year":"2014","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.bone.2015.03.002_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1185\/03007995.2013.763779","article-title":"Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis","volume":"29","author":"Josse","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.bone.2015.03.002_bb0105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2015.03.002_bb0110","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","article-title":"Updated data on proximal femur bone mineral levels of US adults","volume":"8","author":"Looker","year":"1998","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.bone.2015.03.002_bb0115","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/ard.2010.143453","article-title":"Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial","volume":"70","author":"Mok","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.bone.2015.03.002_bb0120","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.bone.2015.03.002_bb0125","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.bone.2015.03.002_bb0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bone.2015.03.002_bb0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bone.2015.03.002_bb0140","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol."},{"key":"10.1016\/j.bone.2015.03.002_bb0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone."},{"key":"10.1016\/j.bone.2015.03.002_bb0150","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328215000782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328215000782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T11:50:16Z","timestamp":1537789816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328215000782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":30,"alternative-id":["S8756328215000782"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2015.03.002","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2015.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}